van Houte Hans
SEC CIK 1817217 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | CFO | 40.2K | — | $2.51M | 51 | 2022-04-30 | 2026-08-04 |
Most active insiders at NRIX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Ring Christine | CLO | — | $3.26M |
| 2 | van Houte Hans | CFO | — | $635.3K |
| 3 | Hansen Gwenn | CSO | — | $630.9K |
Transactions 51
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-04 21:41 | 2026-08-04 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $24.36 | -4,761 | 40.2K | -11% | -$116.0K |
| DM | 2026-07-30 17:58 | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +10.2K | 47.8K | +27% | $0 |
| D | 2026-07-30 17:58 | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $23.38 | -2,845 | 44.9K | -6% | -$66.5K |
| MT | 2026-05-05 19:53 | 2026-05-05 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $16.60 | -14.1K | 37.6K | -27% | -$233.3K |
| DM | 2026-04-30 17:38 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +8,608 | 54.0K | +19% | $0 |
| D | 2026-04-30 17:38 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $16.65 | -2,388 | 51.6K | -4% | -$39.7K |
| DM | 2026-01-30 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +11.5K | 46.2K | +33% | $0 |
| DM | 2026-01-30 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $16.60 | -3,661 | 45.5K | -7% | -$60.8K |
| 2025-11-03 | 2025-11-03 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $12.56 | -6,284 | 37.6K | -14% | -$78.9K | |
| DM | 2025-10-30 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +11.5K | 38.4K | +43% | $0 |
| D | 2025-10-30 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $12.80 | -3,130 | 43.9K | -7% | -$40.1K |
| 2025-08-01 | 2025-08-01 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $11.03 | -5,402 | 35.5K | -13% | -$59.6K | |
| DM | 2025-07-30 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +11.5K | 45.2K | +34% | $0 |
| D | 2025-07-30 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $12.01 | -4,304 | 40.9K | -10% | -$51.7K |
| 2025-05-02 | 2025-05-02 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $11.33 | -6,198 | 33.7K | -16% | -$70.2K | |
| DM | 2025-04-30 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +8,636 | 42.4K | +26% | $0 |
| D | 2025-04-30 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $11.50 | -2,438 | 39.9K | -6% | -$28.0K |
| M | 2025-03-03 | 2025-03-03 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $14.49 | -5,825 | 34.4K | -14% | -$84.4K |
| DM | 2025-01-30 | 2025-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +8,636 | 42.4K | +26% | $0 |
| DM | 2025-01-30 | 2025-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $19.86 | -2,811 | 39.8K | -7% | -$55.8K |
| 2024-11-01 | 2024-11-01 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $24.28 | -3,546 | 33.7K | -10% | -$86.1K | |
| D | 2024-10-30 | 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $24.31 | -2,368 | 37.3K | -6% | -$57.6K |
| DM | 2024-10-30 | 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +8,636 | 33.9K | +34% | $0 |
| 2024-08-26 | 2024-08-26 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $25.22 | -20.0K | 31.0K | -39% | -$504.4K | |
| M | 2024-08-01 | 2024-08-01 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $21.45 | -3,477 | 51.0K | -6% | -$74.6K |
| DM | 2024-07-30 | 2024-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +8,636 | 53.2K | +19% | $0 |
| D | 2024-07-30 | 2024-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $20.67 | -2,490 | 54.5K | -4% | -$51.5K |
| 2024-06-20 | 2024-06-20 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $20.01 | -20.0K | 48.3K | -29% | -$400.2K | |
| 2024-05-02 | 2024-05-02 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $12.83 | -3,499 | 68.3K | -5% | -$44.9K | |
| DM | 2024-04-30 | 2024-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +4,886 | 71.2K | +7% | $0 |
| D | 2024-04-30 | 2024-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $12.04 | -1,387 | 71.8K | -2% | -$16.7K |
| 2024-02-16 | 2024-02-16 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $10.02 | -6,812 | 68.3K | -9% | -$68.3K | |
| DM | 2024-01-30 | 2024-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +4,886 | 76.8K | +7% | $0 |
| D | 2024-01-30 | 2024-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $7.99 | -1,671 | 75.1K | -2% | -$13.4K |
| 2023-12-21 | 2023-12-20 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $10.00 | -3,541 | 71.9K | -5% | -$35.4K | |
| 2023-12-20 | 2023-12-19 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale | $10.00 | -10.9K | 75.5K | -13% | -$109.1K | |
| D | 2023-11-01 | 2023-10-31 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $5.20 | -1,080 | 86.4K | -1% | -$5,616 |
| DM | 2023-11-01 | 2023-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +4,886 | 85.5K | +6% | $0 |
| DM | 2023-08-01 | 2023-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +4,886 | 81.8K | +6% | $0 |
| D | 2023-08-01 | 2023-07-31 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $9.65 | -1,245 | 82.6K | -1% | -$12.0K |
| D | 2023-05-02 | 2023-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +2,886 | 79.7K | +4% | $0 |
| D | 2023-05-02 | 2023-05-01 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $9.88 | -721 | 78.9K | -0.9% | -$7,123 |
| D | 2023-02-01 | 2023-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $11.78 | -924 | 76.8K | -1% | -$10.9K |
| D | 2023-02-01 | 2023-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +2,886 | 77.7K | +4% | $0 |
| D | 2022-11-01 | 2022-10-31 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $12.88 | -739 | 74.8K | -1.0% | -$9,518 |
| D | 2022-11-01 | 2022-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +2,886 | 75.5K | +4% | $0 |
| D | 2022-08-02 | 2022-08-01 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $15.67 | -752 | 72.7K | -1% | -$11.8K |
| D | 2022-08-02 | 2022-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +2,886 | 73.4K | +4% | $0 |
| D | 2022-06-01 | 2022-05-31 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.84 | +68.3K | 70.5K | +3,122% | +$57.4K |
| D | 2022-05-03 | 2022-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | M - OptEx | $0.00 | +2,886 | 2,886 | New | $0 |
| D | 2022-05-03 | 2022-05-02 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | CFO | S - Sale+OE | $11.75 | -697 | 2,189 | -24% | -$8,190 |
Purchase Sale Sale after option exercise All abbreviations